Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.34 +0.73%

+$0.07 today

Market cap
$674.39M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 2.46M

Average 1.66M

KURA Interest Expense

Cost of servicing the company's debt during the period.

Kura Oncology, Inc.NASDAQ: KURA

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $336K fell 12.0% year over year, behind the -8.5% change in trailing-twelve-month interest expense. Sequentially, it fell 2.9% from the prior quarter. Over 3 fiscal years it compounded at +87.6% a year.

Context

  • Interest expense amounted to 2.2% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -12.0% toward the trailing-twelve-month pace of -8.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$336K-2.9% QoQ
Last fiscal yearDec 2025
$1.51M-6.6% YoY
LTMMar 2026
$1.47M-8.5% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.0%——
1 year-6.6%——
3-year CAGR+87.6%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
1.51M USD
Year-over-year change
-6.6%
4-year CAGR
+38.2%

Interest Expense vs competitors

How KURA compares with its peers on the latest reported figures

  • KURA's LTM Mar 2026 interest expense of $1.47M is the 3rd highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -8.5% is the 2nd highest of 4, against a peer median of -12.6%.
  • Interest expense amounts to 2.0% of revenue for KURA, versus a peer median of 1.2%.
KURA Competitors Peer median
Interest Expense for KURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$80.69M +524.3%+120.8%37.2%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$6.9M -12.6%+25.5%2.3%
KURAKura Oncology, Inc.LTM Mar 2026$1.47M -8.5%+87.6%2.0%
VSTMVerastem, Inc.LTM Mar 2026$1.33M -63.4%-18.9%2.7%
HCMHUTCHMED (China) LimitedLTM Jun 2025$0 —+63.9%0.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 ——0.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 ———
TYRATyra Biosciences, Inc.LTM Mar 2026$0 ———
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 ———
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$0 ———
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding KURA) $0-12.6%+44.7%1.2%

Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00053.88M67.48M
Cost of Revenue00849K057K
Gross Profit00(849K)53.88M67.43M
Gross Margin———100.0%99.9%
Research & Development84.72M92.81M115.24M169.97M251.07M
Selling, General & Admin46.54M47.05M50.57M77.11M119.98M
Operating Expenses131.26M139.87M164.96M247.08M371.06M
Depreciation & Amortization558K759K849K848K1.03M
EBITDA(129.49M)(134.85M)(150.23M)(169.5M)(275.83M)
EBITDA Margin———-314.6%-408.7%
Operating Income(131.26M)(139.87M)(165.8M)(193.2M)(303.63M)
Operating Margin———-358.5%-449.9%
Interest Income1.21M4.25M14.72M22.85M26.77M
Interest Expense414K229K1.55M1.62M1.51M
Other Income / Expenses792K4.03M13.17M21.23M25.26M
Income Before Tax(130.47M)(135.84M)(152.63M)(171.97M)(278.37M)
Pre-Tax Margin———-319.1%-412.5%
Income Tax Expense0002.02M297K
Net Income(130.47M)(135.84M)(152.63M)(173.98M)(278.67M)
Net Margin———-322.9%-412.9%
EPS (Basic)(1.97)(2.03)(2.08)(2.02)(3.18)
EPS (Diluted)(1.97)(2.03)(2.08)(2.02)(3.18)
Weighted Avg Shares66.35M66.99M73.23M86.16M87.68M
Weighted Avg Shares (Diluted)66.35M66.99M73.23M86.16M87.68M

Kura Oncology, Inc.

NASDAQ:KURA

Intrinsic Alpha fair value

Locked

Current Price

$7.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.